A preclinical study offers a foundation for a combination strategy in future clinical trials for KRAS mutations.
Penn Medicine
Advertisement
Articles by Penn Medicine
In pilot study, patients saved over an hour of time at every treatment visit.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Dr Pant on the Potential Significance of Daraxonrasib for PDAC Management
2
Breast Cancer Buzz at ASCO 2026: De-Escalation Strategies, Targeted Therapies, and More
3
Epcoritamab Misses Sole US Primary End Point of Overall Survival in R/R DLBCL
4
CHMP Recommends Sacituzumab Govitecan Plus Pembrolizumab for Frontline PD-L1+ Metastatic TNBC
5